Search Results
34 Results Found for “lung neoplasms”
Esophageal cancer (EC) is a major global health concern, ranking as the 11th most commonly diagnosed cancer and the seventh leading cause of cancer-related deaths worldwide, with an estimated 494,320 new cases and 441,994 deaths in 2024.1 Esophageal squamous cell carcinoma (ESCC) remains ...
Metastatic triple-negative breast cancer (mTNBC) is a clinically heterogeneous disease, but compared with other breast cancer subtypes, triple-negative breast cancer (TNBC) is generally associated with a poorer prognosis and has historically had limited therapeutic options.1 The 5-year survival rate remains ...
Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment
This article examines current evidence supporting the use of neoadjuvant immunotherapy in patients with resectable macroscopic stage III melanoma and critically discusses the selection of appropriate adjuvant therapy following surgery. It is written in the context of emerging evidence from ...
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
Early-onset lung cancer is typically defined as occurring in individuals aged 18–50 years, although there is no universally accepted definition.1–3 This entity, though rare, poses unique diagnostic and therapeutic challenges. This article synthesizes current evidence on the unique features and management ...
Head and neck cancer (HNC), with over 946,000 new cases and 482,000 deaths in 2022, is the seventh most common cause of cancer-related deaths globally.1Â Specifically, in the USA, the number of estimated new cases in 2024 was 74,000.2Â Head and neck squamous cell carcinoma (...
Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, ...
Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to ...
To date, the cornerstone of curative treatment in early-stage gastrointestinal (GI) cancers includes surgery and sometimes radiation therapy. Depending on the stage and tumour type, these approaches are often combined with systemic neoadjuvant or adjuvant therapies. After all definitive therapy ...
Neuroendocrine neoplasms (NENs) comprise a heterogenous group of malignancies with diverse clinical behaviour determined by tumour characteristics such as grade, differentiation and primary tumour origin.1 While neuroendocrine carcinomas are poorly differentiated aggressive malignancies, well-differentiated neuroendocrine tumours (NETs) tend to be ...
Somatic DNA mutational analysis has transformed how we characterize existing cancer and select treatments. For example, circulating tumour cell-free DNA (cfDNA) can be used to select targeted therapies, monitor treatment response and detect disease recurrence.1Â However, early attempts with targeted ...
Pancreatic ductal adenocarcinoma (PDA) is predicted to beat colon cancer in terms of total cancer-related deaths in the USA by this year (2020).1Â Given this projected burden of disease, efforts in understanding and developing new treatments for PDA are paramount. In ...
Andrew I Schafer received his MD from the University of Pennsylvania, completed his internal medicine residency at the University of Chicago, and his fellowship in hematology at the Brigham and Women’s (formerly Peter Bent Brigham) Hospital. He rose to ...
Over the course of the last three decades there has been significant improvement in the outcomes of children with non-Hodgkin lymphoma (NHL).1 However, despite varied treatment strategies and sequential clinical trials, the prognosis for one NHL subtype, anaplastic large cell ...
Cavernous sinus syndrome (CSS) is a rare clinical entity characterized by headache, ophthalmoplegia, and neuropathy due to compression of vascular and nerve bundles that course through a narrow anatomical region in the skull.1,2 Myriad conditions lead to this syndrome including ...
Despite substantial advances in cancer diagnosis and treatment, the long-term survival rate for many cancer patients remains dismal.1 More than 90% of cancer-related mortality is ascribed to disease resurgence months or years after adjuvant therapy, either in the form of local ...
Early diagnosis of rare haematological diseases Rare haematological diseases often present ‘in disguise’, with nonspecific symptoms such as pancytopaenia, decreased circulating levels of one or two cell subsets and splenomegaly. Gaucher disease (GD) provides an excellent paradigm when considering challenges ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
